Maravai Lifesciences Holdings, Inc. Stock Price, News & Analysis

Maravai LifeSciences (NASDAQ: MRVI) reported third quarter 2025 results for the period ended September 30, 2025: revenue $41.6M, net loss $(45.1)M, and Adjusted EBITDA $(10.8)M. Nucleic Acid Production revenue was $25.4M (down 52.9% YoY) driven by a lack of high-volume CleanCap commercial vaccine orders, while Biologics Safety Testing revenue was $16.3M (up 7.2% YoY).

The company reiterated full-year 2025 revenue guidance of approximately $185.0M and said TriLink is expected to deliver double-digit sequential revenue growth in Q4 2025; management noted restructuring and cost-reduction initiatives are on track.

Maravai LifeSciences (NASDAQ: MRVI) will announce third quarter 2025 financial and operating results after market close on Thursday, November 6, 2025. The company will host an earnings conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.

Investors may join by phone at (800) 579-2543 or (785) 424-1789 using Conference ID: MARAVAI, or listen via live or archived webcast at https://investors.maravai.com.

Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q2 2025 financial results with revenue declining 31.7% year-over-year to $47.4 million. The company posted a net loss of $(69.8) million, including a $30.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.4) million.

Under new leadership with CEO Bernd Brust and CFO Raj Asarpota, Maravai announced a major restructuring targeting over $50 million in annualized cost savings through labor, facilities, and productivity initiatives. The base business excluding high-volume CleanCap grew 5%, driven by Cygnus products and Biologics Safety Testing segment growth of 9.9%.

The company has withdrawn its 2025 guidance as the new management team conducts a comprehensive business review, with expectations for Net Loss Reduction, Positive Adjusted EBITDA and Free Cash Flow by second half 2026.

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close.

The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day. Investors can join via phone by dialing (800) 267-6316 or (203) 518-9783 with Conference ID MARAVAI, or access the webcast through the "Investors" section of Maravai's website.

Maravai LifeSciences (NASDAQ: MRVI) has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025. He succeeds Kevin Herde, who will transition to an advisory role to support the transition.

Asarpota brings nearly three decades of executive leadership experience, including over 10 years as CFO in life sciences and medical device companies. He will lead Maravai's global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology teams, focusing on driving growth and profitability in nucleic acid technologies and bioprocess impurity analytics.

This CFO transition follows the recent appointment of Bernd Brust as CEO. The company will review its full-year 2025 financial guidance during its second-quarter earnings call in August.

Maravai LifeSciences (NASDAQ: MRVI) has appointed Bernd Brust as its new Chief Executive Officer and Board member, replacing William "Trey" Martin III, effective immediately. Brust brings over 30 years of leadership experience in life sciences, with expertise in transforming businesses into profitable ventures. The leadership change reflects Maravai's focus on accelerating innovation, execution, and financial performance. Brust's customer-centric approach aligns with Maravai's mission to advance scientific discovery in biologics and genomic medicine markets. The company maintains its position in mRNA and bioprocess impurity detection, with plans to enhance manufacturing capabilities. Maravai will review its 2025 financial guidance during the Q2 earnings call in August after Brust conducts a comprehensive business assessment.

TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has entered into a non-exclusive License and Supply Agreement with Quantoom Biosciences for CleanCap mRNA capping technology. The agreement allows Quantoom to integrate TriLink's CleanCap technology into its Ntensify (sa)mRNA production platform. CleanCap technology achieves over 95% efficiency in producing 5′ cap structures and significantly improves mRNA yield and process time compared to traditional methods. The partnership aims to accelerate RNA production and increase accessibility of therapeutics and vaccines globally. CleanCap technology, launched in 2017, is currently used in most approved COVID-19 mRNA and saRNA vaccines. The collaboration focuses on enabling Quantoom's customers to develop (sa)mRNA drugs through clinical development phases using the integrated platform.

Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.

The company demonstrated strong employee engagement with a 95% participation rate in their annual survey and expanded their employee resource programs. In governance, they appointed R. Andrew Eckert as independent Chairman and strengthened their intellectual property position. Sustainability initiatives included enhanced greenhouse gas emissions reporting and renewable energy projects, with their Leland facility's solar panels generating over 180,000 kWh.

Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.

The report details strong employee engagement with a 95% survey participation rate and expanded employee resource initiatives. In governance, the company appointed R. Andrew Eckert as independent Chairman and strengthened its intellectual property position. Sustainability efforts included enhanced greenhouse gas emissions reporting, solar energy generation at the Leland facility, and EV charging stations that saved over 19,000 gallons of gasoline.